New to The Street, one of America's leading business television and multi-platform media brands, today announced a ...

Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish ...

Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types -- N17350 targets a cancer vulnerability, via the ...

Lantern has successfully confirmed PTGR1 as a key biomarker that it intends to use to optimize patient selection based on potential tumor sensitivity to the drug candidate LP-184. LP-184 is a ...

The full manuscript, titled “Enozertinib is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-small Cell Lung Cancer with EGFR Exon 20 and Atypical Mutations,” is available online at Cancer ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...

Pfizer has hired a new oncology commercialization leader to help the business reach its goal of marketing eight blockbuster drugs by 2030. Suneet Varma, currently the commercial president of Pfizer’s ...

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, today announces progress on ...

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

Domestic drug production boost ends import reliance, oncologists call for more clinical trials, stricter quality assurance ...